Successful Treatment of Immune Checkpoint Inhibitor–Induced Bullous Pemphigoid with Omalizumab: A Case Report and Review of the Literature
This case illustrates the challenges of managing ICI-induced BP and highlights omalizumab as a potentially effective treatment option. The study proposes a personalized therapeutic strategy for refractory ICI-induced BP, emphasizing the selection of biologic agents based on specific immune profiles, including serum markers like IgE, eosinophils, and cytokine levels.
Authors
- Sheng‐Hsiang Ma (ORCID: https://orcid.org/0000-0003-1160-5083)
- Jiazhen Chen (ORCID: https://orcid.org/0009-0008-5104-7032)
- Duanni Xu
- Zezhi He
- Jiahui Liu
- Xiangnong Dai
- Yuwu Luo
- Xingdong Ye
Institutions
- Guangzhou Institute of Dermatology (CN)
- Twelfth Guangzhou City People's Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Clinical Cosmetic and Investigational Dermatology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/ccid.s487711
- Citations
- 4
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- Guangzhou Municipal Science and Technology Bureau